References
- KannelWBRisk stratification in hypertension: new insights from the Framingham studyAm J Hypertens2000131 Pt 23S10S10678282
- NickenigGShould angiotensin II receptor blockers and statins be combined?Circulation200411081013102015326080
- O’MearaJGKardiaSLArmonJJBrownCABoerwinkleETurnerSTEthnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA studyArch Intern Med2004164121313131815226165
- StamlerJWentworthDNeatonJDPrevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the multiple risk factor intervention trialAm J Med1986802A33393946459
- CastelliWPAndersonKA population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham studyAm J Med1986802A23323946458
- EmbersonJWhincupPMorrisRWalkerMEbrahimSEvaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular diseaseEur Heart J200425648449115039128
- JacksonRLawesCMBennettDAMilneRJRodgersATreatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular riskLancet2005365945743444115680460
- ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med2005165101147115215911728
- RohHSonHLeeDChangHYunCParkKPharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjectsClin Ther20143681159117025017182
- SonHRohHLeeDChangHKimJYunCParkKPharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjectsClin Ther201335791592223810276
- FabiaMJAbdillaNOltraRFernandezCRedonJAntihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoringJ Hypertens20072571327133617563549
- BrunnerHROlmesartan medoxomil: current status of its use in monotherapyVasc Health Risk Manag20062432734017323586
- BurnierMAngiotensin II type 1 receptor blockersCirculation2001103690491211171802
- PrasadATupas-HabibTSchenkeWHAcute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosisCirculation2000101202349235410821809
- KlingbeilAUJohnSSchneiderMPJacobiJHandrockRSchmiederREEffect of AT1 receptor blockade on endothelial function in essential hypertensionAm J Hypertens200316212312812559678
- JonesPHDavidsonMHSteinEAComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol200392215216012860216
- SchwartzGGBologneseMATremblayBPEfficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trialAm Heart J20041481e415215813
- WernerNNickenigGLaufsUPleiotropic effects of HMG-CoA reductase inhibitorsBasic Res Cardiol200297210511612002257
- WassmannSNickenigGInterrelationship of free oxygen radicals and endothelial dysfunction – modulation by statinsEndothelium2003101233312699074
- SowersJREffects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndromeAm J Cardiol2003914A14B22B
- NickenigGHarrisonDGThe AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesisCirculation2002105339339611804998
- NickenigGHarrisonDGThe AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulationCirculation2002105453053611815439